Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

Stocks opened higher on Wednesday ahead of the Federal Reserve’s interest rate announcement at 2 p.m., which will be followed ...

In work conducted by Jining Medical University investigators, synthesis and optimization of a previously reported ...

Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ago. February saw $8.76 billion in deals, down 69% from January’s $28.63 ...

The U.S. Food and Drug Administration (FDA) has issued its recommendations to vaccine makers on which virus strains to select when manufacturing influenza (flu) vaccines for the 2025-2026 U.S. flu ...

The UEFA Conference League is enabling rising talents from across the continent to thrive. The competition is available to watch across Europe and throughout the world thanks to UEFA's official ...

GSK and Vertex Pharmaceuticals ... s actual appearance on a panel discussion about women’s health at the SXSW conference over the weekend. A detailed post from Regeneron lists several areas ...

GSK Pushes First-in-Class Antibiotic for Uncomplicated UTI By March 26, the FDA is scheduled to release its verdict on GSK’s investigational antibiotic gepotidacin for the treatment of uncomplicated ...

business and civil society delegates gathered at UN Headquarters in New York on Monday for the world’s largest annual conference focused on women’s issues. The 69th session of the UN Commission on the ...